paritaprevir
Jump to navigation
Jump to search
Indications
* including patients with cirrhosis
Dosage
- once a day
- used in combination with ombitasvir & ritonavir in ombitasvir/paritaprevir/ritonavir
Adverse effects
- reactivation of hepatitis B[2]
- may cause liver injury & liver failure independent of hepatitis B[2]
Mechanism of action
More general terms
Component of
- dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR)
- ombitasvir/paritaprevir/ritonavir (Viekira, Technivie)
References
- ↑ Orciari Herman A and Sofair A Viekira Pak Approved for Hepatitis C Physician's First Watch, Dec 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release. Dec 19, 2014 FDA approves Viekira Pak to treat hepatitis C http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm - ↑ 2.0 2.1 2.2 PERSPECTIVES FROM NEW ADVERSE EVENT REPORTS Institute for Safe Medication Practices. Jan 25, 2017 http://www.ismp.org/quarterwatch/pdfs/2016Q2.pdf